Product Images Donepezil Hydrochloride

This appears to be a table that shows the change from baseline in SIB score and the LS mean with standard error for patients receiving either 23 mg/day or 10 mg/day of Donepezil hydrochloride. The table also shows the percent improvement and clinical decline over the course of 24 weeks of drug treatment.*

The text represents a graph that shows the cumulative percentage of patients taking two different doses of Donepezil hydrochloride (23 mg/day and 10 mg/day) for treating Alzheimer's disease. The graph also displays the SIB (Severe Impairment Battery) change from baseline over time. However, without further context or a visual representation of the graph, it is difficult to determine the significance or interpretation of the information presented.*

The text contains a graph showing the cumulative percentage of patients completing six months of a double-blind treatment with changes from baseline in ADCS-ADL-Severe scores. The text also includes some numbers and characters that do not form coherent words or phrases.*

This appears to be a graph or figure showing the cumulative percentage of patients who completed 24 weeks of a double-blind treatment with specified changes from a baseline ADAS-cog score. The graph includes data for a placebo group, a group receiving 5mg/day, and a group receiving 10mg/day. The percentages of patients who completed the study for each group are also included. There is not enough information to determine what specifically the treatment was for or what ADAS-cog scores measure.*

The text describes a figure labeled as "Figure 3" that displays a frequency distribution of CIBIC-plus Scores at week 24 based on the percentage of patients who demonstrated marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, or marked worsening. It appears to be a graph representing the outcomes of a study or experiment.*

This appears to be a section of a scientific report related to drug treatment for patients with ADAS-cog score. It includes a figure depicting the change in ADAS-cog score over time for patients who completed a 15-week study. However, the text appears to be incomplete and contains non-English characters.*

The text describes a figure titled "Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores". The figure shows a graph with the percentage of patients on the Y-axis and time on the X-axis, with values ranging from 0 to 100. The graph also displays a line with data points representing the change from baseline in SIB scores. However, there is not enough visible text to understand specific values or to draw any conclusions.*

This is a medication label for Donepezil 5mg, a white round tablet used to treat dementia (specifically Alzheimer's disease). The label includes information on storage (room temperature of 20°-25°C or 68°-77°F) and expiration (marked as "EXP MM/YY"). The tablet compares to Aricept 5mg and is produced by Alembic Pharmaceuticals Limited. The label also includes a National Drug Code (NDC) number for identification purposes.*